Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Let’s just leave it there now. All I have told you is what I saw. Read my previous posts. I’m not a ramper or a deramper - I’m an investor that has read this BB for the past 18 months and thought that if I posted this then other people with far greater knowledge than me on Avacta could decide if this has any relevance on the LFT story - simple as that.
I am a holder and have been for 18 months. If I wasn’t I wouldn’t have known the significance of where I was going today.
After the recent announcemount I was expecting/hoping to see more than I did but there was at least 150k LFTs in the pallets dated November 1st.
Sorry for only just responding I’ve been driving back from work.
All of the boxes on the pallets have a reference number a ‘lot No’ and 2 dates on them, both dates are November. They’re palletised and wrapped so I couldn’t open the boxes which is why I asked the question about the foils.
I knew I was going to this particular site a couple of weeks back and wondered if I would come across any AffiDX, imagine my surprise when I did.
I do have photographic proof but for obvious reasons I can’t post it in case the company find out and will be able to track it.
This message seems to have been missed with all the moaning and bickering. I’m looking at several crates of Avacta LFTs and trying to work out how many tests are in front of me.
It says 600 foils per box - does anyone know what this indicates?
Just seen this in the daily mail -
The first test to detect active covid from a saliva swab to be rolled out in the UK.
More accurate than predecessors, giving no false positives and the company is a UK company.
Vatic have signed a supply agreement with Abingdon health and currently in tech transfer which should be completed shortly. They’re hoping to roll out 100 million per year.
The Diagnostics Division has launched its first Affimer-powered in-vitro diagnostic product, the AffiDX(R) SARS-CoV-2 antigen lateral flow test which has raised the global profile of the Affimer platform and the Group immensely. It is clear that the Diagnostics Division has the potential to generate significant revenue from sales of this product over a longer period than originally anticipated, creating the basis for a profitable Diagnostics Division.
Hi Sleepydave, not a cross ramp but you did ask - it has to be #OPTI. Significant news due between now and the end of the year which will provide a huge rerate. Even the broker has valued it at 225% above the current share price without the news that is coming.
The questions for me is which of my large holdings will release the news that catapults the share price first - Avacta or Opti.
Q17: Are Mologic a competitor with their own LFT and how will this partnership benefit Avacta when it comes to sales. What, if any, benefits will there be from GAD’s contacts?
Our partnership with Mologic covered the development process and does not include commercialisation of AffiDX. We are working with GAD on the manufacture of the AffiDX test not on commercialisation. GAD’s primary business focus is on Low and Middle Income Countries which, because of price points, are not a focus for Avacta.
Does anyone know when the 912m tender is due to be awarded, I’ve had a look on bidstats but can’t find that info:
What I can find however, is the amount of money that HMRC have spent in the last few months along on testing and private charters to pick up the Chinese crap, mind boggling sums of money!
https://bidstats.uk/tenders/?q=lateral&btype=central-gov#743309311-740098215-71